The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown so far. In very limited studies, the poor clinical outcome of this aggressive variant of multiple myeloma seemed to be ameliorated by the use of the proteasome inhibitor bortezomib. Aiming to provide more consolidated data, this multicenter retrospective survey focused on unselected and previously untreated PPCL patients who had received bortezomib as frontline therapy.

D'arena, G., Valentini, C., Pietrantuono, G., Guariglia, R., Martorelli, M., Mansueto, G. R., Villani, O., Onofrillo, D., Falcone, A., Specchia, G., Semenzato, G., Di Renzo, N., Mastrullo, L., Venditti, A., Ferrara, F., Palumbo, A., Pagano, L., Musto, P., Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party, <<ANNALS OF ONCOLOGY>>, 2012; 23 (6): 1499-1502. [doi:10.1093/annonc/mdr480] [http://hdl.handle.net/10807/3787]

Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party

Mansueto, Giovanna Rosaria;Venditti, Antonella;Ferrara, Ferdinando;Pagano, Livio;
2012

Abstract

The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown so far. In very limited studies, the poor clinical outcome of this aggressive variant of multiple myeloma seemed to be ameliorated by the use of the proteasome inhibitor bortezomib. Aiming to provide more consolidated data, this multicenter retrospective survey focused on unselected and previously untreated PPCL patients who had received bortezomib as frontline therapy.
Inglese
D'arena, G., Valentini, C., Pietrantuono, G., Guariglia, R., Martorelli, M., Mansueto, G. R., Villani, O., Onofrillo, D., Falcone, A., Specchia, G., Semenzato, G., Di Renzo, N., Mastrullo, L., Venditti, A., Ferrara, F., Palumbo, A., Pagano, L., Musto, P., Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party, <>, 2012; 23 (6): 1499-1502. [doi:10.1093/annonc/mdr480] [http://hdl.handle.net/10807/3787]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/3787
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact